Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat autoimmune disease. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore potential combination therapies or indication. Merus N.V. has collaborations and license agreement with Loxo Oncology at Lilly to discover and research novel T-cell re-directing bispecific antibodies. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
IPO Year: 2016
Exchange: NASDAQ
Website: merus.nl
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | $84.00 | Overweight | Piper Sandler |
| 2/7/2025 | $91.00 | Overweight | Wells Fargo |
| 11/21/2024 | $73.00 | Buy | Goldman |
| 10/24/2024 | $72.00 | Buy | UBS |
| 3/28/2024 | $69.00 | Buy | Truist |
| 3/4/2024 | $42.00 → $65.00 | Buy | Needham |
| 11/2/2023 | $45.00 | Buy | Canaccord Genuity |
| 8/21/2023 | Outperform | TD Cowen | |
| 8/2/2022 | $38.00 | Buy | Stifel |
| 2/11/2022 | $45.00 | Outperform | BMO Capital |